Inhaled insulin getting close look by FDA

09/8/2005 | Reuters

The FDA has asked an advisory panel to consider if an inhaled insulin powder developed by Pfizer, Sanofi-Aventis and Nektar Therapuetics could have adverse effects on the lungs or blood sugar levels. The panel is scheduled to review Exubera today, and some analysts project the product, if approved, could generate sales of up to $2 billion a year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ